coprelotamab

**Coprelotamab** is a recombinant humanized IgG1 kappa anti-HER2 monoclonal antibody developed by Genor Biopharma as a proposed biosimilar to trastuzumab. It binds human epidermal growth factor receptor 2 and is intended to reproduce trastuzumab's antitumor activity by antagonizing HER2 signaling and enabling Fc-mediated antibody-dependent cellular cytotoxicity against HER2-overexpressing tumor cells. Clinical development included pharmacokinetic similarity studies versus Herceptin and Phase III studies in HER2-positive metastatic or advanced breast cancer. Public development-tracking sources report that the program was paused pending strategic assessment and is currently classified as terminated or inactive rather than approved. ([link.springer.com](https://link.springer.com/content/pdf/10.1007/s13318-024-00889-1.pdf))

Brand names

Tuznue

Other names

Trastuzumab biosimilar (United BioPharma)Trastuzumab Biobetter (United BioPharma)